Projects per year
Fingerprint
- 1 Similar Profiles
Network
-
Uncovering new checkpoints in natural killer cells to prevent breast cancer metastasis
Witalisz-Siepracka, A., Vallet, S. & Gotthardt, D.
Gesellschaft für Forschungsförderung NÖ
1/12/22 → 30/11/25
Project: Funded Research
-
Untersuchung der Effekte von Immun-Checkpoint Inhibitoren auf den Knochenumbau.
1/11/21 → 30/11/23
Project: Forschungsimpulse › Seed Funding
-
Biomarker- based therapeutic prevention
Vallet, S., Podar, K. & Wiesner, C.
Gesellschaft für Forschungsförderung NÖ
1/12/19 → 1/12/22
Project: Funded Research
-
JunB in multiple myeloma
Podar, K., Vallet, S., Lind, J., Czernilofsky, F., Kollmann, K. & Hundsberger, H.
Land NÖ - WST3 (Abteilung Wirtschaft, Tourismus & Technologie)
1/10/18 → 30/09/22
Project: Funded Research
Research output
-
Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications
Aksoy, O., Lind, J., Sunder-Plaßmann, V., Vallet, S. & Podar, K., Jan 2023, In: Cytokine. 161, p. 156062 156062.Research output: Journal article (peer-reviewed) › Journal article
Open Access1 Citation (Scopus) -
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT
Pleyer, L., Heibl, S., Tinchon, C., Vallet, S., Schreder, M., Melchardt, T., Stute, N., Föhrenbach Quiroz, K. T., Leisch, M., Egle, A., Scagnetti, L., Wolf, D., Beswick, R., Drost, M., Larcher-Senn, J., Grochtdreis, T., Vaisband, M., Hasenauer, J., Zaborsky, N., Greil, R., & 1 others , Mar 2023, In: Cancers. 15, 5, 1388.Research output: Journal article (peer-reviewed) › Journal article
Open Access -
1255 Impact of immune checkpoint inhibitors on bone turnover in cancer patients: prospective clinical study and preclinical correlates
Gassner, T., Vallet, S., Chittilappilly, C., Pirich, T., Lind, J., Aksoy, O., Sunder-Plassmann, V., Hackner, K., Zwickl-Traxler, E., Errhalt, P., Pecherstorfer, M. & Podar, K., 2022, In: Journal for ImmunoTherapy of Cancer. p. A1300-A1300Research output: Journal article (peer-reviewed) › Conference contribution to journal
Open Access -
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group
Leisch, M., Pfeilstöcker, M., Stauder, R., Heibl, S., Sill, H., Girschikofsky, M., Stampfl-Mattersberger, M., Tinchon, C., Hartmann, B., Petzer, A., Schreder, M., Kiesl, D., Vallet, S., Egle, A., Melchardt, T., Piringer, G., Zebisch, A., Machherndl-Spandl, S., Wolf, D., Keil, F., & 3 others , 1 May 2022, In: Cancers. 14, 10, 2459.Research output: Journal article (peer-reviewed) › Journal article
Open Access3 Citations (Scopus) -
On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future
Sunder-Plassmann, V., Aksoy, O., Lind, J., Pecherstorfer, M., Vallet, S. & Podar, K., 2022, In: Expert Opinion on Pharmacotherapy. 23, 12, p. 1425-1444 20 p.Research output: Journal article (peer-reviewed) › Review article
1 Citation (Scopus)